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Challenges for Gene Therapy of CNS Disorders
and Implications for Parkinson’s Disease Therapies
Martin Broadstock1 and Rafael J. Ya´n˜ez-Mun˜oz2
The CNS poses significant challenges for effectivegene therapy, including the presence of the blood–brain
barrier, which prevents the entry of large molecules. Adeno-
associated viral (AAV) vectors have been developed that
demonstrate efficient and stable transgene expression in the
CNS and are the most advanced vector class in clinical ap-
plication, but limitations still manifest. One of them is the
difficulty to achieve extensive transduction volumes. Bearing
this in mind, anti-parkinsonian therapies with relatively re-
stricted targets are particularly suited for initial clinical at-
tempts. In this issue of Human Gene Therapy a long-term
follow-up of one such AAV Parkinson’s disease (PD) clinical
trial is presented (Mittermeyer et al., 2012, this issue). Several
important implications of this work are discussed, including
the need for more widespread transduction to achieve a
clinical benefit. Results obtained with AAV9 demonstrating
blood–brain barrier crossing and extensive CNS transduction
have raised hopes for noninvasive delivery of viral vectors to
wide CNS targets. A second study in this issue of Human Gene
Therapy explores AAV9 efficiency in nonhuman primates and
underscores the importance of delivery route, preexisting
antibody response, and vector tropism (Samaranch et al., 2012,
this issue). Taken together, these two studies showcase
progress and current challenges in clinical and nonhuman
primate CNS gene therapy.
Degeneration of the substantia nigra pars compacta and
subsequent loss of striatal dopamine content is believed to
underpin the cardinal motor symptoms of PD, namely tre-
mor, rigidity, and bradykinesia. Although current pharma-
cotherapies are initially effective, they are associated with a
decline in efficacy as the disease progresses and have a
number of side effects, including hallucinations and uncon-
trollable motor movements (dyskinesias), that may effec-
tively limit the dose of l-DOPA patients can tolerate (Obeso
et al., 2000). Hence the search for alternative treatment, which
needs to be safe and ideally requires a single administration,
provides effective symptomatic relief, and even potentially
halts or reverses the disease process. One way in which this
may be achieved is through the use of gene therapy. The
majority of current gene therapy approaches for the treat-
ment of CNS disorders have focused on the use of AAV
vectors, as they offer stable, long-term gene expression
(McCown, 2011). Such vectors have been administered di-
rectly into the target sites of the CNS through stereotaxic
surgery (Christine et al., 2009; Marks et al., 2010). However,
this invasive approach requires specialist surgical facilities
and accounts for some of the undesirable side effects of gene
therapy reported in the literature (e.g., intracranial hemor-
rhage and edema; Christine et al., 2009).
Nevertheless, localized infusions of vector can efficiently
target specific brain regions, with the associated reduced risk
of adverse events not directly related to vector delivery. The
results of several phase I/II gene therapy trials for Parkin-
son’s have thus far been encouraging, with vectors showing
good safety profiles and being well tolerated in patients.
Current trials can be subdivided into three main strategies:
increasing striatal dopamine content, using aromatic l-amino
acid decarboxylase (rAAV2-hAADC; Genzyme, Cambridge,
MA) alone or a combination of hAADC, tyrosine hydroxy-
lase, and guanosine 5¢-triphosphate cyclohydrolase I (carried
by equine infectious anemia virus-derived lentiviral vector
ProSavin; Oxford BioMedica, Oxford, UK); changing basal
ganglia circuitry by inhibiting the subthalamic nucleus, using
the gene for glutamic acid decarboxylase (AAV-GAD; Neu-
rologix, Fort Lee, NJ); or a trophic factor (neurturin) approach
aiming to improve the nigrostriatal pathway (AAV2-NTN,
CERE-120; Ceregene, San Diego, CA) (Witt and Marks, 2011).
In this issue of Human Gene Therapy, Mittermeyer and
colleagues report a long-term evaluation of a phase I study of
AADC gene therapy for PD (Mittermeyer et al., 2012, this
issue). AADC is the rate-limiting enzyme for the conversion
of l-DOPA to dopamine, and loss of AADC may be associ-
ated with the wearing off of l-DOPA responsiveness in pa-
tients (Ichinose et al., 1994). Thus, restoration of AADC
capacity within the putamen should result in elevated do-
pamine levels in response to exogenous l-DOPA. This study
is a continuation of previous work by this group, who ini-
tially reported findings based on a 6-month follow-up of 10
patients who received either a low dose (9 · 1010 vector ge-
nome copies [VG]) or a high dose (3· 1011 VG) of AADC
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(Christine et al., 2009). Bilateral putaminal convection-
enhanced delivery of AAV-2 vector encoding human AADC,
expected to transduce striatal interneurons that do not de-
generate in idiopathic PD, resulted in about 30% improve-
ment in mean scores, based on the Unified Parkinson’s
Disease Rating Scale (UPDRS), both on and off medication,
without associated dyskinesias. This clinical improvement
was accompanied by robust gene expression, measured by
positron emission tomography (PET) scans using the AADC
tracer [18F]fluoro-l-m-methyltyrosine (FMT). These PET
scans confirmed localized improvements within the puta-
men, which were dose dependent (higher signals were ob-
served in the high-dose group). Although the procedure was
well tolerated, there were hemorrhages in three patients
(asymptomatic in two) that were related to the surgical
procedures in administering vectors. It is noteworthy that
this study excluded patients on the basis of elevated anti-
body titers to AAV2 (Christine et al., 2009), in keeping with
the reported effect of the immune system abrogating the
benefits after gene transfer (Manno et al., 2006).
In the latest long-term follow-up study, the elevated PET
signal induced by AAV2-AADC therapy was observed to
persist over 4 years in both dose groups compared with
baseline and was accompanied by UPDRS improvements in
patients both on and off medication over the first 12 months,
with a slow worsening of symptoms over the remainder of
the study. After 12 months there were no differences in
UPDRS scores or PET signals between the high- and low-
dose groups, which may reflect the unrelenting neurode-
generation seen in PD. The low overall intensity of PET
signal may reflect a need for larger amounts of vector (both
volume and dose) for increased transduction of the putamen
(Mittermeyer et al., 2012, this issue).
This important study has revealed safe, efficient, and es-
sentially permanent gene transfer to cells within the CNS. To
our knowledge this is the longest follow-up study of CNS
gene therapy and is an important milestone in trials for PD.
However, the apparent improvement in symptoms may be
due to the powerful placebo effect seen particularly in pa-
tients with PD. It has previously been reported that a positive
placebo effect was observed in approximately 16% of patients
with PD, with increasing prevalence in those trials involving
surgery (Goetz et al., 2008). The mechanism for this response
appears to be the involvement of cortical pathways impli-
cated in the expectation of improvement, and subsequent
dopamine release within the striatum resulting in improved
motor symptoms of PD (Diederich and Goetz, 2008). As such,
open-label studies may overemphasize the positive results of
gene therapy trials, which are then not reproducible when
investigated in double-blind, sham-surgery controlled ran-
domized trials. This was observed in the initially positive
phase I open-label trial of AAV-NTN, where significant im-
provements in UPDRS scores were observed (Marks et al.,
2008). However, a phase II multicenter, double-blind, ran-
domized controlled trial of AAV-NTN concluded that this
approach was not superior to sham surgery with respect to
the primary outcome measure, a change in UPDRS III (motor)
score in the off-medication state (Marks et al., 2010).
Other potential broader issues needing to be dealt with by
ongoing gene therapy trials for PD include arresting the
underlying disease progression and addressing the non-
motor symptoms of PD, which are receiving increasing at-
tention with regard to quality-of-life issues for patients
(Martinez-Martin, 2011). It is also becoming clearer that PD
is a multiorgan, multicellular disorder that may benefit from
wider application of therapeutic vectors than solely to the
striatum or substantia nigra ( Jellinger, 2012). However, the
prospect for eventual gene therapy to treat PD is promising,
with recent AAV2-GAD gene therapy being effective in a
double-blind, sham-surgery controlled randomized trial of
45 patients (LeWitt et al., 2011). As such, it appears that gene
therapy trials are turning the corner and may soon offer a
valuable weapon in the battle against PD.
With the caveats highlighted by the Parkinson clinical
gene therapy trials in mind, considerable scientific excite-
ment surrounded the first reported AAV serotype able to
cross the blood–brain barrier and efficiently transduce cells
of the nervous system, AAV9 (Duque et al., 2009; Foust et al.,
2009; Manfredsson et al., 2009). The implications of these
reports were that direct surgical targeting may no longer be
required. Instead, a single intravenous injection could deliver
the therapeutic gene throughout the CNS. Encouragingly, it
also appeared that intravenous AAV9 could be detargeted
away from the liver, thus potentially enhancing vector
available for CNS transduction and preventing any hepato-
toxic effects (Pulicherla et al., 2011). These results were tem-
pered by the realization that, similar to other paradigms, the
immune system plays an important role and circulating
neutralizing antibodies against AAV9 can prevent efficient
CNS transduction (Gray et al., 2011b). This is noteworthy,
because approximately 30% of adults are positive for AAV9
antibodies at sufficiently high titers to possibly prevent their
routine clinical use (Boutin et al., 2010). Concerns were also
raised about the high doses of vector required for efficient
CNS transduction: some 1· 1013 VG/kg/mouse. If this were
to be scaled up to humans (approximately 1· 1015 VG), this
may represent a significant technical challenge to achieve
sufficient vector for therapies (Forsayeth and Bankiewicz,
2011). Furthermore, in comparison with the neuronal ex-
pression observed in mice (Duque et al., 2009) there are sig-
nificant intra- and interspecies differences in vector cell
tropism. For example, in the nonhuman primate astrocytes
were reported to be the cell type preferentially transduced by
AAV9 (Gray et al., 2011b). With these three issues in mind—
antibodies, dose, and cellular tropism—Samaranch and col-
leagues, in the current issue of Human Gene Therapy, report
the effects of differing routes of administration of AAV9 in
the nonhuman primate (Samaranch et al., 2012, this issue).
In this report, the authors investigated the effects of in-
traarterial (via the internal carotid artery) or intra-cerebrospinal
fluid (CSF; via the cisterna magna, CM) self-complementary
AAV9 vector administration, in contrast to intravenous injec-
tions, which require large amounts of vector and convey
body-wide transduction. The authors report that intraarterial
injections gave similar efficacy compared with intravenous
administration, with animals expressing the green fluorescent
protein (GFP) reporter gene in the CNS in a dose-dependent
manner. CM injections resulted in many more GFP-positive
cells and greater intensity of GFP expression in the CNS. The
CM-injected monkeys showed much reduced GFP expression
in peripheral organs such as the liver and spleen. Within the brain,
most transduction occurred in astrocytes, regardless of route
of administration, although there were some c-aminobutyric
acid (GABA)-ergic cortical interneurons transduced in the
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CM group. Strikingly, the effects of preexisting AAV9 im-
munity were confirmed in nonhuman primates, with both
high antibody titers (> 1:200) and moderate antibody titers
(1:200) preventing transduction, even when GFP or hAADC
vectors were administered directly into the CSF (Samaranch
et al., 2012, this issue).
These results have important implications for systemic and
intra-CSF AAV9 gene transfer for adult CNS disorders. The
high dose of AAV9 vectors required for efficient transduction
remains a technical challenge, although one that may be
overcome by more advanced production methods. However,
it should be considered that higher doses of vector may
present with an increased incidence of unwanted side effects,
as currently witnessed with pharmacotherapies. More prob-
lematic issues with the use of AAV9 vectors are the effects of
preexisting immunity and cellular tropism. Encouragingly,
low titers of anti-AAV9 antibodies have been reported in
children (Calcedo et al., 2011), and as such, inherited CNS
diseases may offer the most viable targets for current AAV9-
based therapies. This suggestion is supported by the work of
Mattar and colleagues, who described efficient neuronal
transduction after intrauterine gene therapy (Mattar et al.,
2012). Furthermore, site-directed injections have revealed ef-
ficient neuronal expression of AAV9, at least in adult pigs
(Federici et al., 2011). Alternatively, patient groups could be
stratified on the basis of their levels of preexisting immunity.
The issue of cell type specificity may be overcome with tar-
geted promoters such as the human synapsin promoter, or a
fragment of the mouse methyl-CpG-binding protein-2
(MeCP2) promoter, to convey neuronal specificity (Kugler
et al., 2003; Gray et al., 2011a). However, astrocytic expression
per se may not preclude AAV9 for use in some neurode-
generative disorders, including PD, as these may be viable
targets for neurotrophic factor expression (Drinkut et al.,
2011). An alternative approach would be to use RNA inter-
ference to prevent transgene expression in nontarget cell
populations, an approach already being investigated with
AAV9 vectors (Xie et al., 2011). Alternatively, directed evo-
lution of AAV may allow preferential targeting, for instance,
work in the 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-treated primate may reveal additional chimeric vec-
tors suitable for the treatment of PD (Gray et al., 2010; Asokan
et al., 2012). Given that AAV9 binding is mediated by non-
sialylated cell surface glycan receptors, it may be possible to
increase CNS penetrance through enhanced receptor expres-
sion or pharmacological treatments that can enhance AAV
receptor function, for example, recombinant sialidase (Bell
et al., 2011; Shen et al., 2011). Even if AAV9 does not live up to
the initial excitement, one report has suggested that other
recombinant AAV vectors are at least as good as AAV9 in
crossing the blood–brain barrier in neonatal mice (Zhang
et al., 2011). Although interspecies differences in cell tropism
have yet to be described for these agents, novel engineered
vectors may have reduced issues with preexisting immunity
and may therefore offer further options for the treatment of
CNS disorders. The floodgates have now opened, and we
eagerly await further developments in this field.
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